Stephen A. Harrison, MD
Disclosures: Membership on Advisory Committees or Review Panels, Board Membership, etc.-89bio LTD, AKERO THERAPEUTICS, INC, ALTIMMUNE, INC, ARROWHEAD PHARMACEUTICALS, INC|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BOEHRINGER INGELHEIM PHARMA, INC, CHRONWELL, INC, ECHOSENS, NORTH AMERICA, INC, FORESITE LABS, LLC|Membership on Advisory Committees or Review Panels, Board Membership, etc.-GALECTIN THERAPEUTICS, INC, GILEAD SCIENCES, INC, HEPION PHARMACEUTICALS, INC,HISTOINDEX PTE. LTD |Advisor-HUMANA, INTERCEPT PHARMACEUTICALS, INC, INVENTIVA SA, MADRIGAL PHARMACEUTICALS, INC|Membership on Advisory Committees or Review Panels, Board Membership, etc.-MEDPACE, INC, NGM BIOPHARMACEUTICALS, INC, NORTHSEA THERAPEUTICS B.V., NOVARTIS PHARMACEUTICALS CORP|Membership on Advisory Committees or Review Panels, Board Membership, etc.-NOVO NORDISK,POXEL, SAGIMET BIOSCIENCES, SONIC INCYTES MEDICAL CORP|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AXCELLA HEALTH, INC, GENFIT CORP, HIGHTIDE THERAPEUTICS, INC, PATHAI, INC (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-AKERO THERAPEUTICS, INC, CHRONWELL, INC, GALECTIN THERAPEUTICS, INC,|Stocks or stock options, excluding diversified mutual funds-HEPION PHARMACEUTICALS, INC, HEPTA BIO INC, HISTOINDEX, PTE. LTD., NGM BIOPHARMACEUTICALS, INC, |Stocks or stock options, excluding diversified mutual funds-NORTHSEA THERAPEUTICS B.V., SONIC INCYTES MEDICAL CORP|Stocks or stock options, excluding diversified mutual funds-GENFIT CORP (Relationship has ended)|Grant or research support-AKERO THERAPEUTICS, INC, BMS, |Grant or research support-ENYO PHARMA S.A., |Grant or research support-GALECTIN THERAPEUTICS, INC, GENENTECH |Grant or research support-GILEAD SCIENCES, INC, HEPION PHARMACEUTICALS, INC|Grant or research support-INTERCEPT PHARMACEUTICALS, INC, MADRIGAL PHARMACEUTICALS|Grant or research support-NGM BIOPHARMACEUTICALS, INC, NORTHSEA THERAPEUTICS|Grant or research support-NOVO NORDISK, , PFIZER, POXEL, SAGIMET BIOSCIENCES|Grant or research support-VIKING THERAPEUTICS, INC|Grant or research support-AXCELLA HEALTH, INC, CONATUS, GENFIT CORP, HIGHTIDE THERAPEUTICS, INC, IMMURON, SECOND GENOME,|Consulting Fee-Akero, Aligos, Altimmune, Asteroid, Auransa, Bluejay, Boxrer, Corcept|Consulting Fee-Cymbay, Dexcom, Diapharma, Eccogene, Echosens, Enyo, Foresite, Galectin|Consulting Fee-Galecto, Gilead, GSK, GNS, Hepagene, Hepio, Hepta Bio|Consulting Fee-Histoindex, Intercept, Inventiva, Ionis, Madrigal, Medpace, MGGM, Neurobo|Consulting Fee-NGM, Northsea, Novartis, Novo Nordisk, Pfizer, Piper Sandler, Poxel, Regeneron, Sagimet|Consulting Fee-Regeneron, Sagimet, Sonic, Takeda, |Consulting Fee-Tramontane - Kriya, Viking, Asteroid, Calimetrix|Consulting Fee-Alimentiv, Axcekkam CDLF, Cohbar, Genfit, Hightide, Kowa, Perspectum, Silverback, Terns (Relationship has ended) - 04/07/2024

 

 

 

Stephen A Harrison, MD, is the Founder and Chairman of Pinnacle Clinical Research and Co-Founder and Chairman of Summit Clinical Research, LLC in San Antonio, Texas. Dr Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center before completing a 4-year advanced liver disease fellowship at Saint Louis University. Dr Harrison served as a Professor of Medicine at the Uniformed Services University of the Health Sciences and is currently a Visiting Professor of Hepatology at Radcliffe Department of Medicine, University of Oxford.

 

Dr Harrison also served as a Colonel in the United States Army. Retiring in 2016, he concluded more than 20 years of dedicated service to his country. During his army tenure, he served as the Director of Graduate Medical Education at Brooke Army Medical Center, Associate Dean for the San Antonio Uniformed Services Health Education Consortium and Gastroenterology Consultant to the Army Surgeon General. He is a past Associate Editor for Hepatology and Alimentary Pharmacology and Therapeutics. He is internationally known for his work in non-alcoholic fatty liver disease (NAFLD) with over 350 peer-reviewed publications in top-tier journals including the New England Journal of Medicine, Nature Medicine, Lancet, Lancet Gastroenterology and Hepatology, Gastroenterology, Journal of Hepatology and Hepatology. He has an H-Index of 106 with more than 50,000 citations.